HK Stock Market Move | Airdoc-B (02251) rose by over 11%, with a year-on-year revenue increase of 10.8%. The loss greatly narrowed, exceeding 90%.
Eagle Eye Technology-B (02251) surged more than 11%, as of the time of publication, rising by 11.01% to 11.29 Hong Kong dollars, with a trading volume of 2.9675 million Hong Kong dollars.
AIRDOC-B (02251) rose by more than 11%, up to the time of drafting, it rose by 11.01%, to 11.29 Hong Kong dollars, with a trading volume of 2.9675 million Hong Kong dollars.
On the news front, on the evening of March 31, Hengtian Technology announced its performance for the year 2025, with a revenue of 173 million yuan, a year-on-year increase of 10.8%; the net loss attributable to the parent company was 24.975 million yuan, a year-on-year decrease of 90.2%. The announcement pointed out that the decrease in losses during the period was mainly due to the strengthening of channel management, effective management of the pricing system which increased product gross margin; introducing large-scale models across the full chain from research and development, production, sales, to back-end service support, greatly improving efficiency, directly reducing labor costs, reducing reliance on third-party service agencies, and saving service fee expenses.
Related Articles

POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.

Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.

S.F. Holding (06936) spent 187 million yuan to repurchase 4.9224 million A shares on April 1st.
POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.

Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.

S.F. Holding (06936) spent 187 million yuan to repurchase 4.9224 million A shares on April 1st.






